Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae

Antimicrob Agents Chemother. 2013 May;57(5):2388-90. doi: 10.1128/AAC.02399-12. Epub 2013 Feb 25.

Abstract

Ertapenem plus doripenem or meropenem were given in three patients suffering from pandrug-resistant, KPC-2-positive Klebsiella pneumoniae bacteremia (2 patients) and urinary tract infection (1 patient), respectively. All responded successfully, without relapse at follow-up. The results obtained should probably be attributed to ertapenem's increased affinity for the carbapenemases hindering doripenem/meropenem degradation in the environment of the microorganism.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacology*
  • Bacteremia / drug therapy*
  • Bacteremia / microbiology
  • Bacterial Proteins / antagonists & inhibitors
  • Carbapenems / pharmacology*
  • Doripenem
  • Drug Combinations
  • Drug Resistance, Bacterial / drug effects
  • Ertapenem
  • Female
  • Humans
  • Klebsiella Infections / drug therapy*
  • Klebsiella Infections / microbiology
  • Klebsiella pneumoniae / drug effects
  • Klebsiella pneumoniae / enzymology
  • Klebsiella pneumoniae / growth & development
  • Male
  • Meropenem
  • Middle Aged
  • Thienamycins / pharmacology*
  • Treatment Outcome
  • Urinary Tract Infections / drug therapy*
  • Urinary Tract Infections / microbiology
  • beta-Lactamase Inhibitors
  • beta-Lactamases
  • beta-Lactams / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Bacterial Proteins
  • Carbapenems
  • Drug Combinations
  • Thienamycins
  • beta-Lactamase Inhibitors
  • beta-Lactams
  • Doripenem
  • beta-Lactamases
  • carbapenemase
  • Meropenem
  • Ertapenem